These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7878933)

  • 1. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee--Japan.
    Takahashi K; Ochiai T; Uchida K; Yasumura T; Ishibashi M; Suzuki S; Otsubo O; Isono K; Takagi H; Oka T
    Transplant Proc; 1995 Feb; 27(1):1421-4. PubMed ID: 7878933
    [No Abstract]   [Full Text] [Related]  

  • 2. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants.
    Shaffer D; Madras PN; Conway P; Davis C; Simpson MA; Monaco AP
    Transplant Proc; 1997; 29(1-2):342-3. PubMed ID: 9123031
    [No Abstract]   [Full Text] [Related]  

  • 3. A single center experience with mycophenolate mofetil in the prevention of renal allograft rejection.
    Behrend M; Lück R; Köthe P; Pichlmayr R
    Transplant Proc; 1996 Dec; 28(6):3110-1. PubMed ID: 8962205
    [No Abstract]   [Full Text] [Related]  

  • 4. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients.
    Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Iñigo V; Manresa JM; Masramón J
    Transplant Proc; 1999 Sep; 31(6):2259-60. PubMed ID: 10500567
    [No Abstract]   [Full Text] [Related]  

  • 5. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group.
    Transplant Proc; 1997; 29(1-2):348-9. PubMed ID: 9123033
    [No Abstract]   [Full Text] [Related]  

  • 6. Mycophenolate mofetil improves long-term graft survival following renal transplantation in patients experiencing delayed graft function. International Mycophenolate Mofetil Renal Study Groups.
    Cho S; Hodge E; Navarro M
    Transplant Proc; 1999; 31(1-2):322-3. PubMed ID: 10083126
    [No Abstract]   [Full Text] [Related]  

  • 7. Reduction in the incidence of early rejection in cadaveric renal allograft recipients treated with ATGAM induction and sequential mycophenolate mofetil.
    Florence LS; Howard DR; Chapman PH; Lieberman J; Perkinson DT; Marks WH
    Transplant Proc; 1997; 29(1-2):313-4. PubMed ID: 9123016
    [No Abstract]   [Full Text] [Related]  

  • 8. Lymphocyte subsets in renal transplant recipients treated with mycophenolate mofetil.
    François M; Büchler M; Halimi JM; Al-Najjar A; Valentin JF; Thibault G; Lebranchu Y
    Transplant Proc; 2000 Dec; 32(8):2781-2. PubMed ID: 11134803
    [No Abstract]   [Full Text] [Related]  

  • 9. Mycophenolate mofetil in renal transplantation: five years experience.
    Tuncer M; Gürkan A; Erdoğan O; Demirbaş A; Süleymanlar G; Ersoy FF; Akaydin M; Yakupoğlu G
    Transplant Proc; 2002 Sep; 34(6):2087-8. PubMed ID: 12270324
    [No Abstract]   [Full Text] [Related]  

  • 10. [Initial experience with mycophenolate mofetil (RS 61443) after kidney transplantation].
    Friedrich J; Erhard J
    Zentralbl Chir; 1994; 119(1):48-9. PubMed ID: 8147160
    [No Abstract]   [Full Text] [Related]  

  • 11. Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation.
    Munoz MA; Andrés A; Gallego R; Morales E; Morales JM; Aguado JM; Lumbreras C; Torres A; Rodicio JL; Praga M
    Transplant Proc; 2002 Feb; 34(1):97. PubMed ID: 11959202
    [No Abstract]   [Full Text] [Related]  

  • 12. Mofetil mycophenolate in renal transplantation.
    Pretagostini R; Rossi M; Berloco P; Colonnello M; Bruzzone P; Peritore D; Lonardo MT; Cortesini R
    Transplant Proc; 2001; 33(1-2):1082-3. PubMed ID: 11267200
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of antithymocyte globulin treatment of steroid-resistant acute rejection in kidney transplantation.
    Bertoni E; Maccario M; Biagini M; Montagnino G; Piperno R; Tarantino A; Salvadori M
    Transplant Proc; 2001; 33(7-8):3337. PubMed ID: 11750426
    [No Abstract]   [Full Text] [Related]  

  • 14. Mycophenolate approval provides new option for organ-rejection prevention.
    Am J Health Syst Pharm; 1995 Oct; 52(19):2078. PubMed ID: 8535937
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycophenolate mofetil for prevention of acute rejection.
    Moore R; Griffin P; Darby C; Jurewicz A; Lord R
    Lancet; 1995 Jul; 346(8969):253. PubMed ID: 7616827
    [No Abstract]   [Full Text] [Related]  

  • 16. Mycophenolate mofetil monotherapy: an example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients.
    Keunecke C; Rothenpieler U; Zanker B; Schneeberger H; Illner WD; Theodorakis J; Stangl M; Land W
    Transplant Proc; 2000 Feb; 32(1A Suppl):6S-8S. PubMed ID: 10686310
    [No Abstract]   [Full Text] [Related]  

  • 17. Controlled trial of RS-61443 in renal transplant patients receiving cyclosporine monotherapy.
    Salaman JR; Griffin PJ; Johnson RW; Kohlhaw K; Land W; Moore R; Pichlmayr R; Sells R
    Transplant Proc; 1993 Feb; 25(1 Pt 1):695-6. PubMed ID: 8438441
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of mycophenolate mofetil on hematocrit after renal transplantation.
    Chenhsu RY; Wu YM; Min DI; Zimmerman MB
    Ann Pharmacother; 2002 Sep; 36(9):1479-80. PubMed ID: 12196073
    [No Abstract]   [Full Text] [Related]  

  • 19. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection.
    Nicholls AJ
    Clin Biochem; 1998 Jul; 31(5):329-33. PubMed ID: 9721430
    [No Abstract]   [Full Text] [Related]  

  • 20. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation.
    Taylor DO; Ensley RD; Olsen SL; Dunn D; Renlund DG
    J Heart Lung Transplant; 1994; 13(4):571-82. PubMed ID: 7947873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.